Calcimimetics are widely used in patients on dialysis to treat secondary hyperparathyroidism. Our current view is that bone effects are only indirect through parathyroid hormone suppression. However, because bone cells express the calcium-sensing receptor, direct calcium-sensing receptor–mediated effects are also possible. New experimental data demonstrate direct anabolic bone actions of calcimimetics, independent of parathyroid hormone suppression. Because these effects could be clinically useful, further studies are necessary to confirm the validity of this observation.
Direct bone effects of calcimimetics in chronic kidney disease? / Mazzaferro, S.; Pasquali, M.. - In: KIDNEY INTERNATIONAL. - ISSN 0085-2538. - 95:5(2019), pp. 1012-1014. [10.1016/j.kint.2019.01.045]
Direct bone effects of calcimimetics in chronic kidney disease?
Mazzaferro S.
;
2019
Abstract
Calcimimetics are widely used in patients on dialysis to treat secondary hyperparathyroidism. Our current view is that bone effects are only indirect through parathyroid hormone suppression. However, because bone cells express the calcium-sensing receptor, direct calcium-sensing receptor–mediated effects are also possible. New experimental data demonstrate direct anabolic bone actions of calcimimetics, independent of parathyroid hormone suppression. Because these effects could be clinically useful, further studies are necessary to confirm the validity of this observation.| File | Dimensione | Formato | |
|---|---|---|---|
|
Mazzaferro_direct-bone_2019.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
919.16 kB
Formato
Adobe PDF
|
919.16 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
